For International Physicians: New data highlight the potential of the #ShockwaveReducer# in patients with refractory angina, non-obstructive coronary artery disease and coronary microvascular dysfunction (CMD). In this prospective single-arm study of 40 patients, Shockwave Reducer implantation was associated with significant improvements at 4 months. IMR decreased, while CFR, RRR, and MRR increased (all p<0.001). Angina symptoms improved, with median CCS class decreasing from III to II, accompanied by significant improvements in 6mWT distance (p<0.001) and across all 5 SAQ domains (p<0.05 for all). CMD remains a challenging condition with limited treatment options. These findings add to the growing body of evidence suggesting that the #ShockwaveReducer# may offer benefit for this group of patients. Read the full article in Canadian Journal of Cardiology:  Safety Info: CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.